Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma : a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance.
PATIENTS AND METHODS: Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group).
RESULTS: Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189).
CONCLUSIONS: Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 35(2024), 1 vom: 01. Jan., Seite 118-129 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ladetto, M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2023.10.095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364148411 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364148411 | ||
| 003 | DE-627 | ||
| 005 | 20240115231907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.10.095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM364148411 | ||
| 035 | |a (NLM)37922989 | ||
| 035 | |a (PII)S0923-7534(23)04240-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ladetto, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma |b a Fondazione Italiana Linfomi multicenter, randomized, phase III trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance | ||
| 520 | |a PATIENTS AND METHODS: Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group) | ||
| 520 | |a RESULTS: Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189) | ||
| 520 | |a CONCLUSIONS: Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a autologous hematopoietic stem cell transplantation | |
| 650 | 4 | |a consolidation | |
| 650 | 4 | |a follicular lymphoma | |
| 650 | 4 | |a hematological toxicities | |
| 650 | 4 | |a phase III trial | |
| 650 | 4 | |a radioimmunotherapy | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Tavarozzi, R |e verfasserin |4 aut | |
| 700 | 1 | |a Zanni, M |e verfasserin |4 aut | |
| 700 | 1 | |a Evangelista, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrero, S |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, A |e verfasserin |4 aut | |
| 700 | 1 | |a Botto, B |e verfasserin |4 aut | |
| 700 | 1 | |a Bolis, S |e verfasserin |4 aut | |
| 700 | 1 | |a Volpetti, S |e verfasserin |4 aut | |
| 700 | 1 | |a Zilioli, V R |e verfasserin |4 aut | |
| 700 | 1 | |a Puccini, B |e verfasserin |4 aut | |
| 700 | 1 | |a Arcari, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pavone, V |e verfasserin |4 aut | |
| 700 | 1 | |a Gaidano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Corradini, P |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cavallo, F |e verfasserin |4 aut | |
| 700 | 1 | |a Milone, G |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiggi, C |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, A |e verfasserin |4 aut | |
| 700 | 1 | |a Pastore, D |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreri, A J M |e verfasserin |4 aut | |
| 700 | 1 | |a Latte, G |e verfasserin |4 aut | |
| 700 | 1 | |a Patti, C |e verfasserin |4 aut | |
| 700 | 1 | |a Re, F |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetti, F |e verfasserin |4 aut | |
| 700 | 1 | |a Luminari, S |e verfasserin |4 aut | |
| 700 | 1 | |a Pennese, E |e verfasserin |4 aut | |
| 700 | 1 | |a Bossi, E |e verfasserin |4 aut | |
| 700 | 1 | |a Boccomini, C |e verfasserin |4 aut | |
| 700 | 1 | |a Anastasia, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bottelli, C |e verfasserin |4 aut | |
| 700 | 1 | |a Ciccone, G |e verfasserin |4 aut | |
| 700 | 1 | |a Vitolo, U |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 35(2024), 1 vom: 01. Jan., Seite 118-129 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2024 |g number:1 |g day:01 |g month:01 |g pages:118-129 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2023.10.095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2024 |e 1 |b 01 |c 01 |h 118-129 | ||